Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1250791

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Jongsma, Maria M E; Aardoom, Martine A; Cozijnsen, Martinus A; van Pieterson, Merel; de Meij, Tim; Groeneweg, Michael; Norbruis, Obbe F; Wolters, Victorien M; van Wering, Herbert M; Hojsak, Iva et al.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial // Gut, 71 (2020), 1; 34-42 doi:10.1136/gutjnl-2020-322339 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1250791 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Autori
Jongsma, Maria M E ; Aardoom, Martine A ; Cozijnsen, Martinus A ; van Pieterson, Merel ; de Meij, Tim ; Groeneweg, Michael ; Norbruis, Obbe F ; Wolters, Victorien M ; van Wering, Herbert M ; Hojsak, Iva ; Kolho, Kaija-Leena ; Hummel, Thalia ; Stapelbroek, Janneke ; van der Feen, Cathelijne ; van Rheenen, Patrick F ; van Wijk, Michiel P ; Teklenburg-Roord, Sarah T A ; Schreurs, Marco W J ; Rizopoulos, Dimitris ; Doukas, Michail ; Escher, Johanna C ; Samsom, Janneke N ; de Ridder, Lissy

Izvornik
Gut (0017-5749) 71 (2020), 1; 34-42

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Crohn's disease

Sažetak
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Izvorni jezik
Engleski



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Zagreb,
Medicinski fakultet, Osijek,
Klinika za dječje bolesti

Profili:

Avatar Url Iva Hojsak (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Jongsma, Maria M E; Aardoom, Martine A; Cozijnsen, Martinus A; van Pieterson, Merel; de Meij, Tim; Groeneweg, Michael; Norbruis, Obbe F; Wolters, Victorien M; van Wering, Herbert M; Hojsak, Iva et al.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial // Gut, 71 (2020), 1; 34-42 doi:10.1136/gutjnl-2020-322339 (međunarodna recenzija, članak, znanstveni)
Jongsma, M., Aardoom, M., Cozijnsen, M., van Pieterson, M., de Meij, T., Groeneweg, M., Norbruis, O., Wolters, V., van Wering, H. & Hojsak, I. (2020) First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut, 71 (1), 34-42 doi:10.1136/gutjnl-2020-322339.
@article{article, author = {Jongsma, Maria M E and Aardoom, Martine A and Cozijnsen, Martinus A and van Pieterson, Merel and de Meij, Tim and Groeneweg, Michael and Norbruis, Obbe F and Wolters, Victorien M and van Wering, Herbert M and Hojsak, Iva and Kolho, Kaija-Leena and Hummel, Thalia and Stapelbroek, Janneke and van der Feen, Cathelijne and van Rheenen, Patrick F and van Wijk, Michiel P and Teklenburg-Roord, Sarah T A and Schreurs, Marco W J and Rizopoulos, Dimitris and Doukas, Michail and Escher, Johanna C and Samsom, Janneke N and de Ridder, Lissy}, year = {2020}, pages = {34-42}, DOI = {10.1136/gutjnl-2020-322339}, keywords = {Crohn's disease}, journal = {Gut}, doi = {10.1136/gutjnl-2020-322339}, volume = {71}, number = {1}, issn = {0017-5749}, title = {First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial}, keyword = {Crohn's disease} }
@article{article, author = {Jongsma, Maria M E and Aardoom, Martine A and Cozijnsen, Martinus A and van Pieterson, Merel and de Meij, Tim and Groeneweg, Michael and Norbruis, Obbe F and Wolters, Victorien M and van Wering, Herbert M and Hojsak, Iva and Kolho, Kaija-Leena and Hummel, Thalia and Stapelbroek, Janneke and van der Feen, Cathelijne and van Rheenen, Patrick F and van Wijk, Michiel P and Teklenburg-Roord, Sarah T A and Schreurs, Marco W J and Rizopoulos, Dimitris and Doukas, Michail and Escher, Johanna C and Samsom, Janneke N and de Ridder, Lissy}, year = {2020}, pages = {34-42}, DOI = {10.1136/gutjnl-2020-322339}, keywords = {Crohn's disease}, journal = {Gut}, doi = {10.1136/gutjnl-2020-322339}, volume = {71}, number = {1}, issn = {0017-5749}, title = {First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial}, keyword = {Crohn's disease} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.